{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-014407","form_type":"8-K/A","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2022-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.497939+00:00","generated_at":"2026-06-23T21:39:28.591677+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precigen completes $170M sale of Trans Ova Genetics; pro forma shows $213M cash","bullets":["Closed sale of 100% of Trans Ova to Spring Bidco LLC for $170M; net cash proceeds ~$169.5M.","Pro forma cash and equivalents rise to $213.4M from $43.8M as of June 30, 2022.","Pro forma continuing ops loss of $49.2M for H1 2022 vs. historical loss of $36.9M (net of discontinued ops).","Pro forma continuing ops loss of $110.8M for FY2021, compared to historical net loss of $96.8M.","Pro forma balance sheet eliminates $88.9M of assets and $15.1M of liabilities classified as held for sale."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-014407","json":"https://secwatch.observer/filing/0000950103-22-014407.json","markdown":"https://secwatch.observer/filing/0000950103-22-014407.md","text":"https://secwatch.observer/filing/0000950103-22-014407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322014407/0000950103-22-014407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322014407/dp178970_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:39:28.591677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}